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A 54-year-old Korean male with scleroderma-like mani-
festation of primary systemic amyloidosis presented with firm
cutaneous induration of face and distal extremities, subcuta-
neous induration of the trunk and proximal extremities, limited
range of motion in all joints, hoarseness, and dysphagia.
Monthly high-dose intravenous immunoglobulin (hdIVIg) was
given (three treatments, each time administering 0.4 g/kg per
day for five days), and both signs and symptoms began to
improve. However, the quantitative analyses of serum protein
did not improve. Therapeutic plasma exchange (TPE) was per-
formed monthly to clear the elevated serum immunoglobulin,
and after several treatments, their levels normalized and
symptoms were maintained in the improved state for more
than two years. To summarize, hdIVIg and TPE combination
therapy may be used as a safe first-line treatment for patients
with primary systemic amyloidosis presenting with sympto-
matic monoclonal gammopathy.
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INTRODUCTION
Amyloidosis refers to a heterogeneous group of
disorders characterized by extracellular deposition
of proteinaceous fibrillar materials (termed amy-
loid) in various tissues and organs.1 It can be
divided into two major forms: amyloid light chain
(AL) amyloidosis and amyloid A amyloidosis.2
Clinical skin involvement occurs in approximately
25% of patients with AL amyloidosis,3 and com-
mon manifestations include petechiae, purpura,
ecchymoses, papules, nodules, plaques, and tume-
factive lesions; a scleroderma-like manifestation is
rarely seen.4,5
Therapeutic plasma exchange (TPE) has been
proven to be an effective treatment in patients
showing monoclonal gammopathy.6 We applied
TPE to treat an AL amyloidosis patient with
scleroderma-like manifestations because the amy-
loids in AL amyloidosis are derived from the
monoclonal immunoglobulin light chains pro-
duced by plasma cells.
CASE REPORT
A 54-year-old Korean male was first referred to
our department on October 4, 2001, with a history
of hoarseness, difficulty in swallowing, and pro-
gressive generalized hardening of the body that
had progressed over the past two years. The skin
on his face and distal extremities was indurated,
and several brownish and shiny papules were
noted on the forehead and perioral area. On the
trunk and proximal extremities, the skin was
normal in elasticity, but the underlying muscles
were indurated, and almost all of the joints were
restricted in motion (Fig. 1A, Table 1). Quantita-
tive analyses of serum protein revealed concentra-
tions of immunoglobulin G (IgG) of 1,780 mg/dl
and kappa ( ) light chain of 532κ mg/dl (the nor-
mal ranges are 700-1,600 mg/dl and 170-370 mg/
dl, respectively). Serum immunofixation showed a
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characteristic pattern of monoclonal IgG gammo-
pathy, particularly of paraprotein. Laryngosκ -
copic examinations revealed granulomatous
materials deposited in the vocal cords, and nerve
conduction studies showed polyneuropathy of
the sensory nerves. Impaired left ventricular
systolic function and thickening of the left ven-
tricular walls with restrictive filling were noted
upon echocardiography. There were no remark-
able findings in various studies, including a bone
marrow aspiration study, abdominal ultrasono-
graphy, and esophagography. The skin biopsy
specimens showed a deposition of amyloid mate-
rials in the dermis, subcutaneous tissues, and in
the connective tissue septae of the skeletal
muscle by Congo-red stain (Fig. 1C), and it pro-
duced a characteristic apple-green birefringence
when viewed under a polarized light source (Fig.
1D).
After failure to control the symptoms with sys-
temic steroids, colchicine, or cyclophosphamide,
monthly high-dose intravenous immunoglobulin
(hdIVIg) was infused for three courses of treat-
ment (each time giving 0.4 g/kg/day for five
days); the patient noted improvement in subjec-
tive symptoms such as tightness of legs and dys-
phagia, and the range of motion of his joints
began to improve as early as three weeks after the
first treatment (Fig. 1B, Table 1). However, the
elevated IgG and κ light chain levels did not
decrease, despite the symptomatic changes, and
the symptoms progressed with the discontinua-
tion of hdIVIg therapy. Although the patient had
no apparent renal dysfunction, the concern of
potential renal involvement in systemic amy-
loidosis and the possibility that hdIVIg would
enhance that risk made us decide to discontinue
further hdIVIg therapy. To clear the excess serum
immunoglobulin, which was constantly elevated
despite the hdIVIg therapy, monthly TPE was per-
formed, and the normalized serum immunoglo-
bulin levels and the symptoms and signs, in-
cluding dysphagia, tightness of legs, induration of
skin, and the limited range of motion, were main-
tained in an improved state for more than two
years.
DISCUSSION
Most reports on the treatment of primary and
myeloma-associated systemic amyloidosis have
been anecdotal, and responses to treatment are
difficult to assess because of the poor correlation
between amyloid load and organ dysfunction.7
Cytotoxic chemotherapy is the mainstay of treat-
ment, and melphalan, prednisone, colchicine,
penicillamine, azathioprine, vincristine, and cyclo-
phosphamide have been used in the treatment of
systemic amyloidosis. Cohen et al.
8
reported that
Fig. 1. (A) Joints are severely restricted in
motion when fingers are fully extended.
(B) Marked improvement in the range of
motion three weeks after the 3rd hdIVIg
therapy. (C) Biopsy from the lip shows
pinkish amorphous homogeneous masses
of amyloid in dermis, subcutaneous tissue,
and muscle (Congo red stain; original
magnification × 40). (D) Congo red stain
produces apple-green birefringence under
a polarized light microscope (original
magnification× 40).
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colchicine was found to improve life expectancy
in 53 patients with AL amyloidosis. Erikkson et
al.9 proposed the therapeutic implications of 1-α
antitrypsin. More aggressive chemotherapy, my-
eloablation, and autologous bone marrow trans-
plantation have been proposed as novel thera-
peutic approaches.10,11 Immunotoxins directed
against the precursors of the amyloidogenic
plasma cells are under investigation.9 Conflicting
evidence exists concerning vitamin C and vitamin
E.7 Merlini et al.10 showed that doxorubicin
derivatives play a role in enhancing the resorption
of AL amyloid in vitro and in murine models.
HdIVIg has increasingly been used for the
treatment of certain dermatoses, such as bullous
autoimmune diseases and erythema multiforme.
12
Lister et al.13 reported two patients with scleromy-
xedema who showed a dramatic response to
treatment with hdIVIg. Krastev et al.
14
reported a
case of gastrointestinal amyloidosis showing
clinical improvement with hdIVIg treatment, as in
our case.
Although the majority of cases reported to date
show an absence of or only slight adverse side-
effects with hdIVIg, it is suggested that hdIVIg
therapy may enhance the risk of adverse side-
effects, and should be carefully considered in
patients with pre-existent diseases such as con-
gestive heart failure, immobilization, or renal
insufficiency.15 In addition, dysproteinemia due to
hdIVIg therapy itself may result in cast nephro-
pathy and renal failure. Although the patient had
no apparent renal dysfunction, to avoid potential
renal involvement in systemic amyloidosis and
other possible risks of hdIVIg, we decided against
further hdIVIg therapy. Also, considering that
hdIVIg could not effectively reduce the level of
serum paraprotein, TPE seemed to be an effective
and safe alternative for removing the parapro-
teins, which is ultimately necessary to prevent
disease progression. TPE is regarded as being less
effective than hdIVIg therapy for the treatment of
amyloidosis. However, it is effective in patients
with symptomatic monoclonal gammopathy
because it removes the paraproteins very effi-
ciently, particularly in patients who do not re-
spond to drug therapy.4
In conclusion, hdIVIg and TPE combination
therapy may be used as a safe first-line treatment
for patients with primary systemic amyloidosis
presenting symptomatic monoclonal gammo-
pathy. However, long term follow-up is needed to
fully elucidate the effects of combination therapy,
and the application of these treatments in a larger
group of patients is necessary.
Table 1. Estimated Range of Motion of the Joints under Passive Movement
Joints Motion of joints
Range of motion ( )
Normal range
Before treatment Three weeks after the 3rd administration
Elbow Flexion 0 - 120 10 - 120 0 - 150
Extension - 30 - 5 0 - 10
Hand Flexion of MPJ 30 - 90 0 - 90 0 - 90
Flexion of PIP 0 - 80 0 - 90 0 - 100
Thumb Flexion of IP 0 - 50 0 - 50 0 - 80
Hip Flexion 0 - 105 0 - 110 0 - 120
Knee Flexion 0 - 120 0 - 125 0 - 135
Extension - 20 - 5 0 - 10
Ankle Dorsiflexion 0 - 10 0 - 10 0 - 20
Plantar flexion 0 - 15 0 - 30 0 - 50
Data are given in degrees unless otherwise indicated.
MPJ, Metacarpophalangeal joint; PIP, Proximal interphalangeal joint; IP, Interphalangeal joint.
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